Depomed (ASRT) Scheduled to Post Quarterly Earnings on Wednesday

Share on StockTwits

Depomed (NYSE:ASRT) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Depomed (NYSE:ASRT) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.05. The business had revenue of $57.93 million for the quarter, compared to the consensus estimate of $55.51 million.

ASRT opened at $2.85 on Tuesday. The company’s 50 day simple moving average is $3.19. Depomed has a twelve month low of $2.76 and a twelve month high of $9.48.

ASRT has been the topic of a number of recent analyst reports. Zacks Investment Research cut Depomed from a “buy” rating to a “hold” rating in a report on Monday, July 29th. Mizuho cut their price target on Depomed from $6.00 to $3.00 and set a “neutral” rating on the stock in a report on Thursday, May 16th.

In other news, Director William Mckee sold 12,500 shares of Depomed stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $4.70, for a total transaction of $58,750.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

About Depomed

Assertio Therapeutics, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults.

Featured Story: Does a trade war provide a risk to the global economy?

Earnings History for Depomed (NYSE:ASRT)

Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Delta Asset Management LLC TN Has $9.63 Million Stock Holdings in Enbridge Inc
Delta Asset Management LLC TN Has $9.63 Million Stock Holdings in Enbridge Inc
Delta Asset Management LLC TN Reduces Stock Holdings in Lowe’s Companies, Inc.
Delta Asset Management LLC TN Reduces Stock Holdings in Lowe’s Companies, Inc.
Cantillon Capital Management LLC Sells 57,332 Shares of S&P Global Inc
Cantillon Capital Management LLC Sells 57,332 Shares of S&P Global Inc
Delta Asset Management LLC TN Acquires 1,778 Shares of Caterpillar Inc.
Delta Asset Management LLC TN Acquires 1,778 Shares of Caterpillar Inc.
Cantillon Capital Management LLC Reduces Position in Primerica, Inc.
Cantillon Capital Management LLC Reduces Position in Primerica, Inc.
Cantillon Capital Management LLC Sells 29,010 Shares of Armstrong World Industries Inc
Cantillon Capital Management LLC Sells 29,010 Shares of Armstrong World Industries Inc


© 2006-2019 Ticker Report